Health Assessment & Health Promotion Flashcards

1
Q

Purpose of the Health Care Visit:

A

Evaluate for presence of menopause-related signs & symptoms.
Identify risk factors for osteoporosis.
Institute preventive measures for osteoporosis.
Identify risk factors for cardiovascular disease.
Perform a physical exam to screen for coincidental medical and/or gynecological disease.
Teach women preventive measures for common symptoms of menopause.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Purpose of Health Care Visit:

A

Provide an opportunity for women to discuss feelings about body image, emotional issues, life style changes, and sexuality.
Institute medication therapy when appropriate.
Hormone therapy.
Bisphosphonates.
Raloxifene.
Patient education.
Initiate preventive health measures as appropriate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

History Taking:

A

Comprehensive health history with emphasis on following areas:
Woman’s impression of her physical condition and elicit problems relating to:
Presence of hot flushes.
Night sweats.
Insomnia.
Vaginal itching & irritation, dyspareunia.
Angina, palpitations.
Urinary tract problems.
Osteoporotic changes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Woman’s current physical status:

A

LMP – R/O possibility of pregnancy.
Presence of abnormal vaginal bleeding.
Current medications, cigarette use, and alcohol intake.
Ongoing treatment for other health problems.
Nutrition, weight control, diet.
Domestic violence.
Emotional issues.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Personal history for:

A

Cardiovascular problems, hypertension.

Screening for fracture risk:
Bone mass at any point in life is a function of what has already been formed and what has been lost.
Women who haven’t formed adequate peak bone mass in their younger years are at severe risk for fractures later on

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Personal History

A

medical problems that occurred during the adolescent growth spurt:
Disorders that delay or disrupt menstrual function.
Severe dietary deficits.
Physical immobilization.

A careful history can help determine patients who are more likely to be near “fracture threshold” → bones are so brittle that they can snap with a cough or lifting a grocery bag.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Medical History

A
Breast disorders.
Liver disease or tumors.
Gallbladder disease.
Uterine disorders   i.e. -- endometrial cancer, fibroids, previous abnormal pap, history of abnormal vaginal bleeding.
Insulin-dependent diabetes.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Family history:

A

Coronary artery disease.
Breast disease.
Osteoporosis (especially in patient’s mother).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Physical Assessment

A

Baseline height – take actual measurement.

Weight.

Vital signs - Blood pressure, pulse, respirations.

Comprehensive physical exam.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

physical assessment GU

A

evaluate for menopausal changes:
Assess vagina for signs of atrophy.
Evaluate vaginal muscle tone, presence of cystocele or rectocele.
Evaluate uterine size, shape, & consistency.
A pap smear must be taken adequately to sample squamocolumnar junction which recedes into the cervical canal.
Evaluate adnexa → any palpable adnexa must be referred to MD for evaluation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Laboratory Assessment

A

Annual CBC.
FSH level?
In premenopausal women gonadotropic levels fluctuate throughout the transition from last regular period to menopause.
FSH & LH increase during a hot flash but when flush disappears, levels return to those characteristic of young, cycling women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Assessment and amenorrhea

A

No definitive way to distinguish transient amenorrhea from the amenorrhea that defines menopause.
Obtaining serum hormone assays not of much predictive value during menopausal transition → may still have further ovulatory cycles despite an elevated FSH or low estradiol level.
In the first year after menopause, FSH levels are 10-15X higher than in early follicular phase levels in young woman.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Lab values

A
Blood lipids - annually or prn.
Fasting plasma glucose every 3 - 5 years for women with one or more of the following risk factors:
Family history.
Obesity.  
History of gestational diabetes.
Liver function studies prior to initiation of HT.
Thyroid testing:
Every other year after age 60.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pap Test

A

After age 30 with 3 normal pap results in a row  repeat pap every 2-3 years.
Women over 70 with 3 or more consecutive normal pap results in last 10 years  may chose to stop cervical screening.
Screening after total hysterectomy (with removal of cervix) not necessary unless surgery was done as a treatment for cervical cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Mammogram:

A

Every 1-2 years for women between 40-49 & yearly for those with risk factors.
Annually for women over 50 years of age.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Colorectal testing:

A

Annual stool specimen - evaluate for occult blood.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Colonoscopy

A

Every 3-5 years after the age of 50 in patients with average risk of colorectal cancer.
Annually for patients with a history or family history of colorectal cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Bone density testing:

A

Height loss not evident until bone loss is 25%
DEXA scan – dual energy xray absorptiometry
Most accurate & safest way to measure bone density in order to detect or manage osteoporosis.
Scan site should be determined by history or specific risk factors.
Proximal femur → best single determinant of high fracture risk.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Management Plan for Women with Normal Exam

A
  1. Provide contraception during climacteric phase.
    OC’s safe in non-smoking women over 35 up to time of menopause.
  2. Always rule out pregnancy with amenorrhea until diagnosis of menopause is made.
  3. Teach SBE, schedule yearly mammograms.
  4. Schedule baseline DEXA scan; or repeat scan prn.
  5. Schedule colonoscopy prn.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Management Plan for Women with Normal Exam

A
  1. Teach Kegel exercises. (50-100 every day)
    Strengthens support muscles.
    Minimize urinary tract problems.
  2. Advise continued, regular sexual activity.
    Helps to prevent atrophic vaginitis.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Management Plan for Women with Normal Exam

A
  1. Nutritional counseling:
    Good nutrition → helps to alleviate symptoms & enhances quality of life.
    Well-rounded low fat diet.
    Weight control.
    Diet full of “high-stress” foods (i.e. - sugar, fat, alcohol, caffeine) can accelerate health problems related to the aging process.
    Include food sources of calcium, use supplementation as needed.
    Soy products can be a source of estrogen.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Management Plan for Women with Normal Exam

A
  1. Educate about the importance of regular exercise.
    Prevent/alleviate symptoms of osteoporosis.
    Cardiovascular health.

10.Educate about what is “normal” during this stage of life.
Physically.
Psychologically.
Encourage use of support groups to discuss the different aspects of this stage of life.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Management Plan for Women with Normal Exam

A
  1. Stress the importance of regular health care visits to practitioner.
  2. Instruct patient to return for any worsening menopausal symptoms.
  3. Discuss:
    Risks/benefits of hormone therapy (HT); hormone replacement therapy (HRT).
    Current recommendations on its use in the management of menopausal symptoms.
    Provide informed consent for any women choosing to use HT.
    Informed consent must also include discussion of WHI findings.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Osteoporosis Management:

A

Prevention – educate young women and their parents about importance of good nutrition & regular exercise.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Osteoporosis Management:

A

Provide calcium intake adequate to prevent bone loss:
Adequate intake:
1000mg/day – perimenopause; women on HT.
1200mg/day – women over age 50
1,500mg/day – women not taking HT; women over age 65.
Optimal source of calcium is dietary especially dairy products.
The average diet has 400mg of elemental calcium/day.
8oz milk  300mg elemental calcium.
Calcium carbonate has 400mg elemental calcium in 1000mg.
Tums has 200mg of calcium per tablet.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Vitamin D to diet

A

Helps to maintain blood calcium levels in normal range.
If vitamin D is lacking, calcium is not well-absorbed.
Vitamin D – synthesized from skin’s exposure to UV rays in sunlight.
@ 15 minutes of sun exposure daily is considered adequate.
For women at risk of inadequate sun exposure:
400 I.U. daily – age 51-70
600 I.U. daily – over 70

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Vitamin D

A

Vitamin D – can be toxic in high amounts:
Tolerable upper limit → 2000 I.U. daily
Most people should avoid daily amounts over
1000 I.U. daily.
Dietary options:
Egg yolks, liver & oily fish (herring, salmon).
Fish oil (cod liver oil) – 1 teaspoon = 1100 I.U. vitamin D.
Milk fortified with vitamin D = would have to drink 1 quart of milk to = 400 I.U.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Osteoporosis Guidelines (cont)

A

Regular weight-bearing exercise.
Diet should not be excessive in fiber, protein, & carbohydrates  these foods interfere with calcium absorption.
Stop smoking.
Decrease caffeine & alcohol intake.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Medications:

for osteoporosis

A

Non-hormonal bisphosphonates
Prevention or treatment.
Increases bone mass in lumbar spine & reduces fracture incidence.
Must be taken on an empty stomach at least 30 minutes prior to breakfast & only with water.
Must remain upright at least 30 minutes & until after the first food of the day to avoid irritation to the esophagus.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Medication for osteoporosis

A

Fosamax
Prevention – 5 mg daily or 35 mg weekly.
Treatment – 10 mg daily or 70 mg weekly.
Fosamax plus D
Treatment – 70 mg/2800 I.U. once weekly.
Boniva
Prevention/treatment – 2.5 mg daily or 150 mg once monthly.
Actonel
Prevention/treatment – 5 mg daily or 35 mg weekly.
Actonel with calcium
Prevention/treatment – 35 my once weekly on day 1, then 500 mg calcium once daily on days 2-7 each week.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

medications for osteoporosis

A

Reclast®
Given once a year – IV medication given over 15 minutes.
Osteoporosis – 5mg year.
Supplement with calcium and Vitamin D.
Possible adverse reaction – osteonecrosis of the jaw.

32
Q

other mediations

A

Selective estrogen receptor modulators (SERMs)- Raloxifene (Evista)
Mimic estrogen in some parts of the body & block estrogen’s cancer-promoting effects in others.
Drug’s selection to act as either an agonist or antagonist based on molecular structures of various receptor sites in the body.

33
Q

other medications Evista

A

Evista
Goal of therapy  reduce rate of bone resorption & decrease rate of overall bone turnover.
Increases bone mineral density & also promotes a decrease in total & LDL cholesterol levels.
Does not affect endometrial or breast tissue.
Dosage – 60mg daily & can be taken without regard to the time of day or meals.

34
Q

more information on Evista

A

Causes a 10% decrease in prothrombin time.
Need to avoid long periods of immobility & should discontinue drug use 3 days prior to a period of prolonged immobility.
Contraindicated in women who have past or present histories of deep vein thrombosis, pulmonary emboli, or retinal vein thrombosis.
Should not be taken in addition to HT.
Does not relieve hot flashes & may even increase incidence.
Potential teratogen.

35
Q

Cardiovascular Disease Management

A

1 cause of death among postmenopausal women.

Patient education:
Most women’s symptoms are ignored  they tend to be sicker by the time cardiovascular disease is recognized.

Refer for cardiac workup for any identifiable symptoms and/or those with increased risk factors.

36
Q

life style changes

A
Assist women to evaluate life style & change those factors which can be changed:
Diet.
Weight.
Smoking.
Stress.
37
Q

Hot Flashes/Night Sweats Management

A

Hormone therapy → still remains best treatment.
Clonidine Hydrochloride (Catapres) 0.1mg tablet; cut into quarters and taken PO TID.
Avoid precipitating factors: i.e., hot drinks or meals, alcoholic beverages, emotional upsets, hot weather or hot room, bed that is too warm.
Dress in layers, shower prn.
Lifestyle changes: daily exercise, yoga, meditation.

38
Q

Nutrition:

A

Increase vitamin E in diet. (Peanuts, soybeans, spinach, wheat germ, vegetable oils – but must watch fats!!!!)
Assure adequate vitamin B complex. (Whole grains, yogurt, wheat germ, liver, brewer’s yeast)
Assure adequate fluid intake – at least 8 glasses of water daily.
Selective Serotonin Reuptake Inhibitors (SSRIs)- being studied in the treatment of vasomotor symptoms.

39
Q

Atrophic Vaginitis/Vulvovaginal Burning Management

A

Estrogen vaginally:
Use of vaginal estrogens does not significantly raise serum levels of estrogens.
Premarin Cream 1/2 applicator – 1-2times/week.
Estradiol tablet vaginally 2 times/week.
Use exogenous lubrication during sex.
Frequent sexual activity.

40
Q

Phytoestrogens’ in diet may offer natural lubrication for genital tissues.

A

Plant-derived estrogens that are structurally or functionally equivalent to estradiol → produce estrogen effects.
Soy products, flax seeds, cereal brans, barley, corn, wheat, oats, legumes, apples, peanuts, cashews, almonds, chick peas, blue grass & clover.
Use with caution with women with history of breast cancer.

41
Q

Urinary Symptoms Management

A

May be avoided with HT or vaginal estrogen.
Cystocele/urethrocele present → refer for surgical consult.
Kegel exercises.

42
Q

Psychological Changes & Mood Changes Management

A

Provide opportunity for ventilation of feelings.
Observe for symptoms of clinical depression.
Stress reduction techniques.
Refer for therapy.
Be alert for signs of domestic violence & refer appropriately.

43
Q

Hormone Therapy (HT)

A

Up until 2002, HT advocated to be ‘cure all’ for all menopausal symptoms.

Based on results from the Women’s Health Initiative (WHI) → use of HT controversial.

44
Q

HT traditionally advocated in management of perimenopausal women:

A

Osteoporosis prevention.
Newer drugs developed which prevent & treat osteoporosis.
Cardiovascular disease prevention.
Research has shown this to be false.
Physical symptoms: hot flashes/flushes; vaginal atrophy; skin changes.
Emotional symptoms – depression; sleep deprivation; loss of libido.
Women seem happier taking HT.

45
Q

Benefits of HT:

A

Decreases the severity & frequency of vasomotor symptoms.
Often improves a woman’s mood.
Decreases genitourinary atrophy.
Decreases severity or prevents osteoporosis by:
Assisting in absorption of calcium and preventing its excretion.
Stimulating calcitonin.
Blocking the effect of bone-reabsorbing para-thyroid hormone.
Inhibiting breakdown of old bone

46
Q

Disadvantages of HT

A

Use of exogenous estrogen without progestin increases the incidence of endometrial cancer.
Increased risk (2-5X) of gallbladder disease.
Possible side effects: breast tenderness, nausea, edema, breakthrough bleeding, stimulation of fibroids, monthly withdrawal bleed.
Possible increased risk of breast cancer. (controversial)
Updated information from the Nurses’ Study shows that after 10 years of estrogen use a woman’s risk of dying from breast cancer was 45% higher than what nonusers face.

47
Q

Contraindications to Use of HT:

A

History or presence of estrogen-dependent neoplasm.
Presence of undiagnosed vaginal bleeding.
History or current presence of thromboembolism.
Active or severe liver disease.
Fear of a woman who is unresponsive to education.

48
Q

Relative Contraindications to HT:

A
Insulin-dependent diabetes.
Gallbladder disease.
Uterine fibroids or endometriosis.
Severe hypertriglyerimia.
History of endometrial cancer without hysterectomy.
49
Q

Prescribing HT

A

No official standard or protocol for administering HT.
No conclusive studies to indicate which regimen is most beneficial.
Most commonly prescribed regimens:
Cyclic.
Continuous.
Continuous combined.

50
Q

Hormone Therapy

A

Women without a uterus need estrogen only.

Women with uterus need estrogen and progestin.
Progestin added to prevent excessive proliferation of endometrium stimulated by estrogen.

51
Q

Estrogen Dosage

A

Types of estrogen:
Estrogens in contraceptives:
Synthetic & nonsteroidal
More potent & more hepatic effects.

Estrogens in HT:
Natural steroidal compounds derived from animal sources or produced in labs.
Closely mimic a woman’s endogenous estrogen.

52
Q

Estrogen Dosage

A

Estrogen dosage dependent on reason for use:
Begin with the smallest dose:
Gives woman time to adjust to a smaller change in estrogen level.
Allows titration to the smallest dose that relieves symptoms.

53
Q

Cyclic Regimen:

Estrogen Dosage

A

Estrogen is taken days 1-26 of each calendar month:
Conjugated estrogen (Premarin) 0.625mg
Estradiol (Estrace) 1mg
Ethinyl Estradiol (Estinyl) 0.02mg
Mestranol 0.2mg
PLUS
Progestin is taken days 16 (or 19) to 25 each calendar month:
Medroxyprogesterone acetate (Provera) 10mg
Norethindrone

54
Q

Cyclic Regimen:

Estrogen Dosage

A

No hormones taken for rest of month.
Woman should have a withdrawal bleed 2-5 days after the end progestin therapy.
Women need to understand there is no risk of pregnancy even though they will still have a monthly “period”.

55
Q

Continuous Regimen: of estrogen

A

Estrogen dosage is taken every day of the calendar month & progestin is added from days 1-10.
There will be a withdrawal bleed after taking the progestin.

56
Q

Continuous Combined Regimen:
Method A
of Estrogen

A

Estrogen dosage & 2.5mg of Provera taken daily.
Progestin → prevents proliferative effect of estrogen & maintain atrophic endometrium without a bleeding cycle.
May experience some irregular bleeding (50-80%) during the first 3 months but once body adjusts to the hormone levels there should be no bleeding at all.
Felt that this method is most agreeable to women:
No monthly bleeding.
Easy to remember when to take pills.
Trade name: Prempro.

57
Q

Method B

Estrogen

A

Constant administration of estrogen with intermittent progestin pulsed on a 3 days off, 3 days on.
Administration of continuous estrogen & intermittent progestin:
Sensitizes the tissue to progestin during the estrogen-only phase.
Permits lower progestin doses to be used while increasing sensitivity to & optimizing effect of progestin.
Lower doses of progestin – favorable effects & better tolerability.
Trade name – Ortho Prefest – estradiol & norgestimate.

58
Q

Method C

Estrogen

A

Continuous daily estrogen dosage with 20mg Provera added for 14 days every 3 months.
Followed by a 7 day drug-free period → withdrawal bleeding.
Aim of long cycle therapy is to reduce exposure to progestins & to reduce the frequency of bleeding cycles.
One study showed that women prefer this quarterly regimen by 4:1.
Studies indicate that a 3-4 month cycle may be safe with out sacrificing the protective effects of progestin on the endometrium.

59
Q

Angeliq®

A

New HT formulation
.5mg drospirenone/1mg estradiol
Continuous method.
Precautions – need to monitor potassium levels if taking other medications that can increase serum level.

60
Q

Transdermal Estradiol

A

Proven clinically effective in relieving menopausal symptoms.
Transdermal route provides a more normal estrone to estradiol ratio than oral estrogens.
“Estraderm”
0.05mg to 1mg daily
Gives desirable effects while avoiding the pharmacologic effects of oral estrogens on hepatic proteins.

61
Q

Transdermal Estradiol

A

Skin patch placed on skin every 3 days.
Used continuously → symptoms may return when removed due to rapid decrease in estradiol levels.
Endometrial proliferation is normal:
Oral progestin must be given for 10-13 days to induce a withdrawal bleed.

62
Q

Climara”

A

Estrogen patch changed weekly.

May keep estrogen levels more stable.

63
Q

Vaginal ring

A

Femring”
Estradiol acetate vaginal ring – 0.05mg/day; 0.10mg/day.

Indications for use:
Treatment of moderate to severe vasomotor symptoms.
Treatment of moderate to severe symptoms of vulvar & vaginal atrophy.

64
Q

Vaginal ring

A

Must add progestin for women with intact uterus:
Ten or more days of a cycle of estrogen.
Daily with estrogen in a continuous regimen.

Has same potential risks of combined estrogen/progestin therapy.

65
Q

Initiation of HRT

A

Some practitioners recommend the following tests prior to the initiation of HRT, some feel that in the absence of abnormal vaginal bleeding or high risk factors, they are unnecessary:
Endometrial biopsy.
Progesterone challenge test.

66
Q

Hormone Therapy Follow Up

A

Instruct patient to contact practitioner with any episode of abnormal vaginal bleeding.
Some irregular bleeding with continuous therapy may be expected in the months shortly after initiation.

67
Q

Hormone Therapy Follow Up

A

Side effects can be managed in a variety of ways:
Change dosage of estrogen, type given, or route.
Side effects such as depression & other psychological changes → progestin may be changed to an other type or dosage may be decreased.

68
Q

Endometrial surveillance is required for:

A

Episodes of unusual bleeding → heavy bleeding at time of withdrawal bleeding or bleeding during anytime other than expected time.
Any woman with a uterus who takes unopposed estrogen.
Includes any woman who has discontinued unopposed estrogen → risk of endometrial hyperplasia continues for an indefinite time after discontinuation of therapy
Types of endometrial evaluation:
Endometrial biopsy/sampling.
Transvaginal ultrasound – endometrium over 5mm thickness needs EMB.

69
Q

Recommended visit schedule:

A

Visits every 3 months in the first year, assess for:
Changes in B/P.
Success of symptom relief.
Untoward side effects.

May take 3-4 visits to facilitate:
Adequate counseling.
Titration of therapy.
Compliance with treatment program.

70
Q

Recommended visit schedule:

A

Then, visits yearly or twice yearly with same comprehensive assessment provided at the initiation of therapy.

Recommended to schedule regular measurement of bone density every 2-3 years for women on HT.

71
Q

Duration of HRT

A

Variable → dependent on symptoms.

Indefinite duration if prescribed for prevention of genital atrophy, osteoporosis.

Before WHI results → was also recommended for indefinite duration for cardiovascular purposes.

72
Q

Patient Education About HRT

A

Risks & benefits.
Explain physiology of monthly withdrawal bleed & impossibility of pregnancy.
Discuss possible side effects & have woman keep a record of any untoward symptoms.
Have woman record frequency & duration of symptoms being treated.
Teach about importance of reporting any incidence of breakthrough bleeding → must be investigated with an endometrial biopsy.

73
Q

Women’s Health Initiative (WHI)

A

Randomized, multicentered, double-blind, placebo controlled study of postmenopausal women sponsored by the NIH to examine the causes & ways to prevent:
Heart disease,
Breast & colon cancer,
Osteoporosis.
373,092 women screened, ages 50-79 years old.

74
Q

Women’s Health Initiative (WHI)

A

One arm of WHI studied healthy & ethnically diverse patients with an intact uterus, aged 50-70, taking either HT or placebo.

Objective → to assess the major health benefits & risks of the most commonly used combined hormone preparation in the US over 8 years.

Prempro – formulation used in study.
Felt that results would apply to other HT formulations.

75
Q

Women’s Health Initiative (WHI)

A

5.2 years after initiation of study(2002), the combined HT portion of the trial was halted due to the observations that the risks of this intervention outweighed its benefits.

A separate arm of WHI study, initiated at the same time, was designed to examine the use of estrogen therapy without a progestin.
Stopped in 2004.
Results showed that there was no cardiovascular benefit & an increased risk of stroke.

76
Q

WHI Data

A

Absolute risk for any individual woman remains small.

When numbers are extrapolated to the 6 million women in the US who are estimated to be using the HT studied:
More than 11,000 events per year.
Over course of 5 years – as many as 57,000 events or 1 in 100 women could be expected to have an occurrence.

77
Q

Controversies @ WHI:

A

Studied one type of HT only.
Study was well done but statistics used to analyze data are complex → difficult to replicate or repudiate WHI findings.
Did not report on menopausal sx → some women with moderate to severe menopausal sx where discouraged from participating in WHI.
Emphasized that HT should not be used for prevention of disease but gave no guidelines as to when to use it for tx of sx.
Only 1 in 6 participants were within 5 years of menopause → could results have been different if HT was started earlier?